Oral semaglutide was approved by the FDA in December 2025 as a once-daily pill (25 mg), intended to limit excess body weight ...
VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery ...
More than 80% relative bioavailability compared with injectable obesity therapy, well above the roughly 30% reported for existing microneedle patches and setting a new global benchmark A potential ...
MELBOURNE, Australia, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Gelteq Limited (GELS) (“Gelteq” or the “Company”), a clinical and science-based company specialising in gel-based oral delivery solutions, today ...
Gastroretentive drug delivery systems (GRDDS) represent a sophisticated approach to oral medication by extending the retention time of dosage forms in the stomach. This increased residence time can ...
FeSSIF pH of 5, bile salt; 15 mM of bile salt and 3.75 mM of lecithin FaSSIF-V2 pH of 6.5; 3 mM of bile salt and 0.2 mM of lecithin [32–36] FeSSIF-V2 pH 5.8; 10 mM of bile salt; 2 mM of lecithin and ...
PharmTech spoke with Dr. Asma Patel, VP Global Commercial and Scientific Consulting–Drug Product, to find out how the growth ...
A new review uncovers how common natural supplements can both protect and endanger health, depending on dose, duration, and delivery—and points to next-gen technologies as the key to unlocking their ...
VANCOUVER, BC / ACCESS Newswire / January 19, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback